[{"indications": "Indications\u00a0moderate to severe hypertension (adjunct); heart failure (with long-acting\r\nnitrate, but see section 2.5.5); hypertensive emergencies (including during pregnancy) (see section 2.5)", "name": "HYDRALAZINE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.1 Vasodilator antihypertensive drugs", "HYDRALAZINE HYDROCHLORIDE"], "cautions": "Cautions\u00a0coronary artery disease (may provoke angina, avoid after myocardial infarction\r\nuntil stabilised), cerebrovascular disease; occasionally blood pressure reduction too rapid even\r\nwith low parenteral doses; manufacturer\r\nadvises test for antinuclear factor and for proteinuria every 6 months\r\nand check acetylator status before increasing dose above 100\u00a0mg daily, but evidence of clinical value unsatisfactory; interactions: Appendix 1 (hydralazine)", "side-effects": "Side-effects\u00a0tachycardia, palpitation, flushing, hypotension,\r\nfluid retention, gastro-intestinal disturbances; headache, dizziness;\r\nsystemic lupus erythematosus-like syndrome after long-term therapy\r\nwith over 100\u00a0mg daily (or less in women and in slow acetylator individuals)\r\n(see also notes above); rarely rashes, fever, peripheral neuritis,\r\npolyneuritis, paraesthesia, arthralgia, myalgia, increased lacrimation,\r\nnasal congestion, dyspnoea, agitation, anxiety, anorexia; blood disorders\r\n(including leucopenia, thrombocytopenia, haemolytic anaemia), abnormal\r\nliver function, jaundice, raised plasma creatinine, proteinuria and\r\nhaematuria reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2539.htm", "doses": ["By mouth, hypertension, 25\u00a0mg twice\r\ndaily, increased to usual max. 50\u00a0mg twice daily (see notes above)", "Heart failure (initiated in hospital) 25\u00a0mg 3\u20134 times daily,\r\nincreased every 2 days if necessary; usual maintenance dose 50\u201375\u00a0mg\r\n4 times daily", "By slow intravenous injection, hypertensive\r\nemergencies and hypertension with renal complications, 5\u201310\u00a0mg diluted\r\nwith 10\u00a0mL sodium chloride 0.9%; may be repeated\r\nafter 20\u201330 minutes (see Cautions)", "By intravenous infusion, hypertensive\r\nemergencies and hypertension with renal complications, initially 200\u2013300\u00a0micrograms/minute;\r\nmaintenance usually 50\u2013150\u00a0micrograms/minute"], "pregnancy": "Pregnancy\u00a0neonatal thrombocytopenia reported, but risk should\r\nbe balanced against risk of uncontrolled maternal hypertension; manufacturer\r\nadvises avoid before third trimester"}]